Related references
Note: Only part of the references are listed.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
Jin Li et al.
BMC CANCER (2010)
Mode of action and clinical impact of VEGF signaling inhibitors
Jens Soltau et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Bevacizumab - In first-line treatment of advanced and/or metastatic renal cell carcinoma
James E. Frampton et al.
BIODRUGS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling
Yoko Hasumi et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2
N. C. Ton et al.
CLINICAL CANCER RESEARCH (2007)
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
Katherine Holmes et al.
CELLULAR SIGNALLING (2007)
Vascular endothelial growth factor trap in non-small cell lung cancer
GregoryJ. Riely et al.
CLINICAL CANCER RESEARCH (2007)
Challenges for patient selection with VEGF inhibitors
R. Longo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A phase I dose-escalation study of weekly IMC-1121 B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
R. Cohen et al.
EJC SUPPLEMENTS (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Molecular regulation of vessel maturation
RK Jain
NATURE MEDICINE (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells
T Takahashi et al.
EMBO JOURNAL (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
